

# The carbohydrate-insulin model: a physiological perspective on the obesity pandemic

David S Ludwig,<sup>1,2,3</sup> Louis J Aronne,<sup>4</sup> Arne Astrup,<sup>5</sup> Rafael de Cabo,<sup>6</sup> Lewis C Cantley,<sup>7</sup> Mark I Friedman,<sup>8,9</sup> Steven B Heymsfield,<sup>10</sup> James D Johnson,<sup>11,12</sup> Janet C King,<sup>13</sup> Ronald M Krauss,<sup>14,15</sup> Daniel E Lieberman,<sup>16</sup> Gary Taubes,<sup>9</sup> Jeff S Volek,<sup>17</sup> Eric C Westman,<sup>18</sup> Walter C Willett,<sup>3,19</sup> William S Yancy, Jr,<sup>18</sup> and Cara B Ebbeling<sup>1,2</sup>

<sup>1</sup>New Balance Foundation Obesity Prevention Center, Boston Children's Hospital, Boston, MA, USA; <sup>2</sup>Department of Pediatrics, Harvard Medical School, Boston, MA, USA; <sup>3</sup>Department of Nutrition, Harvard TH Chan School of Public Health, Boston, MA, USA; <sup>4</sup>Comprehensive Weight Control Center, Weill Cornell Medicine, New York, NY, USA; <sup>5</sup>Department of Nutrition, Exercise, and Sports, University of Copenhagen, Copenhagen, Denmark; <sup>6</sup>Translational Gerontology Branch, National Institute on Aging, NIH, Baltimore, MD, USA; <sup>7</sup>Department of Medicine, Weill Cornell Medicine, New York, NY, USA; <sup>8</sup>Monell Chemical Senses Center, Philadelphia, PA, USA; <sup>9</sup>Nutrition Science Initiative, San Diego, CA, USA; <sup>10</sup>Metabolism & Body Composition Laboratory, Pennington Biomedical Research Center, Baton Rouge, LA, USA; <sup>11</sup>Diabetes Research Group, Life Sciences Institute, University of British Columbia, Vancouver, British Columbia, Canada; <sup>12</sup>Institute for Personalized Therapeutic Nutrition, Vancouver, British Columbia, Canada; <sup>13</sup>Department of Nutritional Sciences & Toxicology, University of California Berkeley, Berkeley, CA, USA; <sup>14</sup>Department of Pediatrics, University of California San Francisco, San Francisco, CA, USA; <sup>15</sup>Department of Medicine, University of California San Francisco, San Francisco, CA, USA; <sup>16</sup>Department of Human Evolutionary Biology, Harvard University, Cambridge, MA, USA; <sup>17</sup>Department of Human Sciences, Ohio State University, Columbus, OH, USA; <sup>18</sup>Department of Medicine, Duke University School of Medicine, Durham, NC, USA; and <sup>19</sup>Channing Division of Network Medicine, Brigham and Women's Hospital, Boston, MA, USA

## ABSTRACT

According to a commonly held view, the obesity pandemic is caused by overconsumption of modern, highly palatable, energy-dense processed foods, exacerbated by a sedentary lifestyle. However, obesity rates remain at historic highs, despite a persistent focus on eating less and moving more, as guided by the energy balance model (EBM). This public health failure may arise from a fundamental limitation of the EBM itself. Conceptualizing obesity as a disorder of energy balance restates a principle of physics without considering the biological mechanisms that promote weight gain. An alternative paradigm, the carbohydrate-insulin model (CIM), proposes a reversal of causal direction. According to the CIM, increasing fat deposition in the body—resulting from the hormonal responses to a high-glycemic-load diet—drives positive energy balance. The CIM provides a conceptual framework with testable hypotheses for how various modifiable factors influence energy balance and fat storage. Rigorous research is needed to compare the validity of these 2 models, which have substantially different implications for obesity management, and to generate new models that best encompass the evidence. *Am J Clin Nutr* 2021;00:1–13.

**Keywords:** obesity, weight loss, dietary carbohydrate, energy balance, macronutrients, endocrinology, insulin, glucagon, incretins, scholarly discourse

## Introduction

The last century has witnessed fundamental developments in our understanding of the biological basis of obesity. Many lines of investigation demonstrate that body weight is controlled

by complex and interconnected systems involving multiple organs, hormones, and metabolic pathways. Common genetic variants, acting on these systems, may explain >20% of the population-level variation in BMI (1). Rare mutations have been identified that cause obesity in humans (2). Animal models have been generated in which mutation of a specific gene yields susceptibility to, or protection from, obesity (3). These genetic and molecular insights lay the foundation for many scientific models of obesity, helping to explain individual susceptibility to changing environmental conditions. However, in view of the rapid worldwide increase in BMI despite relatively stable genetic susceptibility, scientific explanations for the pandemic must consider environmental factors.

During the last century, 2 models addressing environmental causes of obesity have emerged. In the dominant energy balance model (EBM), energy-dense, tasty, modern processed foods drive

The authors reported no funding received for this study.

AA and DSL are Associate Editors of *The American Journal of Clinical Nutrition* and were not involved in the editorial evaluation of this manuscript.

Supplemental Tables 1 and 2 and Supplemental Figure 1 are available from the “Supplementary data” link in the online posting of the article and from the same link in the online table of contents at <https://academic.oup.com/ajcn/>.

Address correspondence to DSL (e-mail: [david.ludwig@childrens.harvard.edu](mailto:david.ludwig@childrens.harvard.edu)).

Abbreviations used: CIM, carbohydrate-insulin model; EBM, energy balance model; GI, glycemic index; GIP, glucose-dependent insulinotropic polypeptide; GL, glycemic load; GLP-1, glucagon-like peptide-1; UCP-1, uncoupling protein-1.

Received June 25, 2021. Accepted for publication July 26, 2021.

First published online 0, 2021; doi: <https://doi.org/10.1093/ajcn/nqab270>.

a positive energy balance through increased intake, and thereby result in fat deposition. In the carbohydrate-insulin model (CIM), a crucial effect of diet is metabolic, by influencing substrate partitioning. Rapidly digestible carbohydrates, acting through insulin and other hormones, cause increased fat deposition, and thereby drive a positive energy balance.

In this review, we provide the most comprehensive formulation of the CIM to date, argue that the CIM better reflects knowledge on the biology of body weight control than the EBM, specify testable hypotheses to help resolve controversies, and call for constructive discourse among scientific camps on this question of critical public health importance.

## Obesity Conceptualized as an Energy Balance Disorder

Obesity is commonly considered a disorder of energy balance. Surrounded by highly palatable, heavily marketed processed foods, many people consume more energy than they burn—an imbalance exacerbated by sedentary lifestyles—with the surplus deposited into body fat. According to this view, the foundation of obesity management is control of energy balance by decreasing intake (“eat less”) and increasing expenditure (“move more”) (Supplemental Table 1). For instance, the USDA Dietary Guidelines for Americans 2020–2025 state that, “Losing weight ... requires adults to reduce the number of calories they get from foods and beverages and increase the amount expended through physical activity” (4). A 2013 expert report from several major professional health associations asserts, “To achieve weight loss, an energy deficit is required” [High evidence strength] (5). An influential textbook concludes, “All diets that result in weight loss do so on one basis and one basis only: they reduce total calorie intake” (6).

Importantly, the EBM considers all calories metabolically alike for practical purposes (7). Thus, specific foods or diets may produce variable amounts of weight gain or loss, but virtually only through energy intake related to hunger, satiation, satiety, hedonic effects, or “passive overconsumption” (8). Dietary treatment focuses on behavioral strategies to help people reduce energy intake, especially of the energy-dense, tasty, processed foods thought to drive a positive energy balance, and to manage adverse effects (e.g., hunger).

## Tautologies and Other Limitations of the EBM

### Energy balance and body weight

The appealing simplicity of the EBM belies an inherent tautology. Weight gain (or more precisely, fat gain) can occur only with a positive energy balance, in the same way that a fever can occur only if the body generates more heat than it dissipates. However, these reiterations of the law of energy conservation ignore causality. During the pubertal growth spurt, energy intake exceeds expenditure as body energy stores increase. Does increased consumption drive growth or does growth drive increased consumption? Neither possibility violates laws of physics, but the 2 perspectives have fundamentally different physiological bases and implications. Because the relation between energy balance and weight change is inseparable, statements regarding

the importance of a negative balance provide no meaningful information about etiology.

### Palatability and food intake

Regarding dietary drivers of obesity, common versions of the EBM focus on the variety and availability of “hyper-palatable” (9), energy-dense, processed foods (Supplemental Table 1). Clearly, people tend to eat more of the foods that they find tasty, and palatability seems to influence short-term food selection and energy intake. However, surprisingly little evidence relates palatability directly to chronic overconsumption (i.e., relative to energy requirements) in laboratory animals or humans under normal conditions (10–12).

Compared to a standard diet, a cafeteria diet composed of a variety of presumably palatable human “junk foods” causes rodents to gain weight (13). Importantly, this diet differs in macronutrients, sugar, saturated fat, and fiber; differences in composition, not palatability, appear to cause the weight gain (10, 14, 15). To examine this issue, Tordoff et al. (10) added highly palatable nonnutritive flavors to a standard rodent diet. When offered a choice, mice showed a strong, persistent preference for the flavored over the unflavored diet. However, the flavored diet increased neither food intake nor weight gain. In a complementary design, Ramirez (15) reported that rats rejected a bitter liquid diet in favor of a plain solid diet of the same nutrient composition when given a choice, but that rats given only the bitter liquid diet increased energy intake and weight compared with those given only the solid diet.

As reviewed by Johnson and Wardle (11), no interventional studies in humans have demonstrated a causal relation between palatability and obesity, controlling for confounding factors such as macronutrient composition. Moreover, major putative contributors to palatability—dietary fat (16), energy density (17), food variety (18), and food processing per se (19, 20)—have not been shown to cause long-term weight gain.

The very notion of palatability seems to lack an operational definition beyond “fast foods,” foods high in “fat, sugar, and salt,” or “ultra-processed” foods (9). In fact, palatability is not a fixed property of food, but rather modifiable through learning and influenced by physiological state. In humans, insulin administration associated with mild hypoglycemia preferentially activates limbic-striatal brain regions, promoting a greater desire for high-calorie foods in general and possibly high-carbohydrate foods (21–23). In the absence of clear correlates to intrinsic food properties, hyper-palatable foods have been defined as those that drive food intake—another tautology of the EBM, which simultaneously attributes increased food intake to hyper-palatable foods.

### Anomalies

By focusing on energy balance—characteristically through conscious control, as highlighted in Supplemental Table 1—the basic formulation of the EBM essentially disregards knowledge about the biological influences on fat storage (24, 25). Moreover, a central conundrum is to understand why the so-called body weight “set point” (7) has increased rapidly among genetically stable populations. In the 1960s, the average man in the United

States weighed ~75 kg. Providing excess dietary energy to increase his weight to 90 kg would have elicited biological responses (e.g., decreased hunger, increased energy expenditure) to resist that gain. Today, the average man weighs ~90 kg; restricting energy to reduce his weight to 75 kg would elicit opposite responses (26–30). By excluding a metabolic effect of diet, common versions of the EBM offer no explanation for what changes in the environment have dysregulated the biological systems that counteract energy imbalance and resist weight change.

Furthermore, conceptual adoption of the EBM has failed to stem the obesity pandemic. Governments and professional health organizations heavily promote energy restriction (especially with low-fat diets) and exercise; nutrition labels on packaged foods prominently display calorie content; and personal responsibility to avoid excess weight gain is emphasized in patient care. Nevertheless, obesity prevalence continues to increase worldwide, prompting spectacularly complex formulations of the EBM addressing myriad biological, behavioral, environmental, and societal factors converging on energy balance (**Supplemental Figure 1**), with questionable practical translation.

### The CIM as a Physiological Explanation for the Obesity Pandemic

Like the EBM, the CIM posits that changes in food quality drive weight gain. However, according to the CIM, hormonal and metabolic responses to the source of dietary calories, not merely calorie content, lie upstream in the mechanistic pathway. In other words, the CIM proposes a reversal of causal direction: over the long term, a positive energy balance does not cause increasing adiposity; rather, a shift in substrate partitioning favoring fat storage drives a positive energy balance, as shown in **Figure 1**. Among modifiable factors, dietary glycemic load (GL) has central importance.

GL is defined as the arithmetic product of total carbohydrate amount and glycemic index (GI—a measure of how foods with controlled amounts of carbohydrate raise postprandial blood glucose) (31). GL is a validated predictor of postprandial glycemia with consumption of typical foods, meals, or eating patterns (32–34). High-GL foods include processed grains, potato products, and foods with a high free sugar content (34). Most fresh whole fruits, minimally processed grains, legumes, nuts, and nonstarchy vegetables have moderate or low GL. Fats and proteins, with no direct impact on postprandial blood glucose, have a nominal GL of 0.

The rapid absorption of glucose after consumption of a high-GL meal increases insulin secretion, suppresses glucagon secretion, and elicits a glucose-dependent insulinotropic polypeptide (GIP)-dominant incretin response (35–37). This highly anabolic state, for the first hours after eating, promotes avid uptake of glucose into muscle, liver, and adipose and stimulates lipogenesis in liver and adipose. Three hours after eating, most of the nutrients from a high-GL meal have been absorbed from the digestive tract (38). However, the persistent anabolic actions from this hormonal response slow the shift from uptake to release of glucose in liver and fatty acids in adipocytes. Consequently, total metabolic fuel concentration in the blood (from glucose, nonesterified fatty acids, and ketones) decreases rapidly in the late postprandial phase, possibly to concentrations below that in the

fasting state (39–41). The brain perceives this signal as indicating that critical tissues (e.g., liver) (24) are deprived of energy—a state of “cellular semistarvation” as it has been termed (42)—and may respond to the metabolic challenge with a counter-regulatory hormone response (39). Simultaneously, hunger and cravings for high-GL foods (i.e., those that rapidly raise blood glucose) increase, setting the stage for a vicious cycle. Energy expenditure may also decline related to decreased fuel availability, hormonal (e.g., thyroid) effects on metabolic pathways and thermogenic tissue, or compensatory adaptations (e.g., in autonomic tone) affecting the postprandial state, resting energy expenditure (43), muscular efficiency (44), or physical activity level (45).


Thus, the marked increase in GL across the population since the low-fat diet era—due to a concurrent increase in total carbohydrate and the exceptionally high GI of modern processed carbohydrates (46, 47)—produces a sequence of pathophysiological events that limits metabolic fuel availability to critical oxidative or energy-sensing tissues, especially in the late postprandial phase, driving a positive energy balance (31, 48). Beyond GL, the CIM provides a conceptual framework for understanding how other dietary components [e.g., fructose (49–52), protein and fatty acid type, fiber, food order within a meal (53)], behaviors [e.g., meal timing (54), circadian rhythm, physical activity], and environmental exposures [e.g., endocrine disruptors (55)] may affect body weight through associated mechanisms (e.g., de novo lipogenesis, intestinal function and microbiome, muscle insulin resistance, chronic inflammation, epigenetic modifications) rather than via direct effects on intake and expenditure.

This reversal of causal direction, although provocative regarding obesity, seems obvious in some other physiological states. The growth of a child drives increases in intake over time. Similarly, fetal growth, with uptake of metabolic fuels from the maternal circulation, drives overeating (relative to expenditure) in the mother, not the converse.

If the CIM is substantially correct, then the strategy to produce a negative energy balance through conscious control of food amount and physical activity level is likely to fail for many people. Restricting energy intake when consuming a high-GL diet would neither lessen the predisposition to fat storage nor diminish hunger during dieting. Rather, by further reducing metabolic fuel availability, hunger would increase and energy expenditure may decline. In contrast, weight reduction produced by carbohydrate restriction would decrease the insulin-to-glucagon ratio, enhance lipolysis and fat oxidation, and result in lower spontaneous food intake. Restriction of carbohydrate intake to very low amounts with consumption of a ketogenic diet may elicit additional mechanisms involving the biological actions of ketones (56), a possibility beyond the scope of this review.

### Predictions and Testable Hypotheses Arising from the CIM

The mechanistic relations depicted in **Figure 1** lead to numerous testable hypotheses (**Supplemental Table 2**). Key findings from laboratory animal and human research are considered below, according to the corresponding numbers in Supplemental Table 2.



**FIGURE 1** Dynamic phase of obesity development in the carbohydrate-insulin model. The relation of energy intake and expenditure to obesity is congruent with the conventional model. However, these components of energy balance are proximate, not root, causes of weight gain. In the compensatory phase (not depicted), insulin resistance increases, and weight gain slows, as circulating fuel concentration rises. (Circulating fuels, as measured in blood, are a proxy for fuel sensing and substrate oxidation in key organs.) Other hormones with effects on adipocytes include sex steroids and cortisol. Fructose may promote hepatic de novo lipogenesis and affect intestinal function, among other actions, through mechanisms independent of, and synergistic with, glucose. Solid red arrows indicate sequential steps in the central causal pathway; associated numbers indicate testable hypotheses as considered in the text. Interrupted red arrows and associated numbers indicate testable hypotheses comprising multiple causal steps. Black arrows indicate other relations. ANS, autonomic nervous system; GIP, glucose-dependent insulinotropic peptide.

### 1) Hormonal response to GL

The effects of GL on pancreatic hormone and incretin secretion are well established. As reviewed by Unger (35) 50 y ago, carbohydrate increases the insulin-to-glucagon ratio by not only stimulating insulin secretion, but also paracrine suppression of glucagon secretion. After a 60% compared with 20% carbohydrate meal, the integrated insulin-to-glucagon ratio was 7-fold higher in adults habituated to a high- compared with a low-carbohydrate diet (40). GL also affects incretin hormone secretion. Oral glucose or a high-GI meal rapidly stimulates GIP secretion, produced in the proximate small intestines; conversely, a low-GI meal has a greater effect on glucagon-like peptide-1 (GLP-1), produced in the distal intestines (36, 37).

### 2) Insulin and tissue-specific insulin sensitivity

Insulin sensitivity is commonly measured at the whole-body level, obscuring critical differences among tissues. Jeanrenaud and colleagues (57, 58) infused rats with insulin by minipump, resulting in well-tolerated hypoglycemia. By day 4 of infusion, glucose utilization, glucose transporter type 4 (GLUT4) expression, lipoprotein lipase activity, and lipogenesis were increased in adipose tissue, whereas muscles developed insulin resistance. These contrasting effects persisted when hypoglycemia was prevented by glucose infusion. Dallon et al. (59) showed that insulin administration reduced uncoupling protein-1 (UCP-1) and mitochondrial respiration in brown adipose tissue. Within the physiological range, insulin regulates energy expenditure (60) at least in part by suppressing UCP-1 mRNA, via peroxisome proliferator-activated receptor  $\gamma$  (PPARG) upregulation, in brown and white adipose tissues in mice—a mechanism that has been recapitulated in cultured 3T3L1 preadipocytes (61).

### 3) Tissue-specific insulin sensitivity and fat storage

Greater insulin sensitivity in white adipose tissue relative to metabolically active or energy-sensing tissues will alter substrate partitioning in favor of fat deposition. In support of this prediction, mice with adipose-specific ablation of the insulin receptor have reduced adiposity without change in energy intake; they are also protected against age-related metabolic abnormalities (62). Conversely, ablation of the insulin receptor in muscle or the central nervous system increases adiposity (63, 64).

### 4) Insulin, glucagon, and adiposity

In rodents, chronic insulin treatment increases food intake and adiposity, and these effects are dissociable. Torbay et al. (65) gave rats daily insulin or saline injections, keeping food intake the same between groups. After 4 wk, the insulin-treated rats had increased fat mass and reduced carcass protein. Consistent with this finding, mice with genetically reduced insulin secretion have higher energy expenditure and are protected from diet-induced obesity (61, 66, 67).

In humans, insulin and drugs that increase insulin secretion or adipose insulin sensitivity cause weight gain, whereas those that decrease insulin secretion [including  $\alpha$ -glucosidase inhibitors (68), which functionally lower the GI of starch] cause weight loss (69). Patients with type 1 diabetes undergoing intensification

of insulin therapy for 2 mo experienced a 2.4-kg increase in body fat, associated with decreased energy expenditure and therefore not fully attributable to changes in dietary intake and urinary glucose excretion (70). Genetic variants associated with increased insulin secretion predict weight gain, including in a bidirectional Mendelian randomization study (71, 72). Pancreatic tumors that secrete insulin may cause weight gain, whereas those that secrete glucagon cause weight loss (73).

### 5) GIP-dominant incretin secretion and fat storage

The cardiometabolic benefits, including weight loss, of GLP-1 agonism are widely recognized. Recently, the adverse effects of GIP, the incretin with the most potent influence on insulin secretion (74), have come to attention, motivating a search for therapeutic antagonists. GIP administration promotes preadipocyte differentiation and fat storage, and, in the brain, inflammation and insulin resistance. GIP receptor knockout mice are protected against diet-induced obesity (36, 75–78).

### 6) GL, metabolic fuels, food preference, and energy balance

Consumption of a high- compared with a low-GL meal results in reduced circulating metabolic fuel concentration after 3–5 h (39–41, 79), associated with altered substrate partitioning, reduced energy expenditure, and a counter-regulatory response (31, 39, 41, 80, 81). Furthermore, spontaneous transient declines in blood glucose predict hunger, meal initiation or requests, and energy intake (82–84). Insulin administration, which lowers the concentration of all the metabolic fuels, causes hunger and possibly a preference for high-GL foods (21–23). Indeed, endogenous hyperinsulinemia may mediate the cravings and binge-eating behaviors associated with high-GL foods through similar mechanisms (85, 86). Hunger has also been observed with drugs that block sensing or oxidation of metabolic fuels (87–90), with a preference for carbohydrate in some experimental settings (91, 92).

### 7) GL, energy balance, and obesity

In animals, high- compared with low-GI diets increase adiposity independently of energy intake, in association with lower physical activity level (45, 93–96). Studies comparing high- with low-carbohydrate diets in animals have produced heterogeneous results (97, 98), an issue considered below.

Most but not all acute studies in humans report reduced hunger or energy intake in the late postprandial state after low-compared with high-GI meals (31, 99). Low- compared with high-carbohydrate diets also increase total energy expenditure after 2–3 wk (100). Over the long term, high-fat diets result in more weight loss than high-carbohydrate diets (16, 101–104), contrary to expectation from considerations of energy density. Furthermore, studies suggest a unique diet–phenotype interaction, in that individuals with high insulin secretion or other abnormalities of glucose homeostasis appear especially susceptible to adverse metabolic responses and weight gain when consuming a high-GL diet (96, 105–110). In ad libitum-fed male monkeys, a higher-GL/high-sugar diet compared with a lower-GL/low-sugar diet increased adiposity without increasing total energy intake through age 20 y (111). However, the chronic effect

of GL on body composition in humans, with control for energy intake, has not been determined.

## 8) Causal direction

In experimental models of obesity, metabolic defects involving substrate partitioning and energy expenditure may manifest without (or before) increased food intake, demonstrating the conceptual plausibility of this fundamental feature of the CIM (60, 112–114). This sequence of events is well established in experimental ventromedial hypothalamic obesity (42, 48, 115–119). Immediately after injury to the ventromedial hypothalamus, hyperinsulinemia develops without systemic insulin resistance, and sympathetic nervous system tone is decreased. Importantly, spontaneous physical activity is reduced during development of ventromedial hypothalamic obesity and increased fat deposition occurs even with restriction of food intake to that of controls. (Prevention of hyperinsulinemia after hypothalamic damage diminishes but does not abolish hyperphagia or increased adipose tissue lipogenesis, demonstrating how other influences on adipocyte metabolism, such as autonomic dysfunction, could alter fuel partitioning and cause obesity consistent with the CIM.) A similar sequence of metabolic events, independent of increased food intake, occurs during development of obesity with insulin administration (65, 120) and with a high-GI diet (45, 93–96). Pragmatic and ethical limitations preclude such experiments in humans. In a prospective observational study and a Mendelian randomization analysis, increased adiposity better predicted decreased physical activity level than the converse (121, 122).

## Criticisms

With recent attention to the CIM (123), numerous reviews claim to have “falsified” the model, or otherwise challenged its validity (7, 124–135). However, specific criticisms are based on weak or misleading evidence, leading to the following misinterpretations.

### **Genetic variants associated with adiposity relate primarily to the central nervous system, not the adipocyte as would be predicted by the CIM (134, 135)**

The brain expresses genes controlling virtually all aspects of energy metabolism, beyond those that may affect hunger directly, including through hormonal and autonomic control of pancreatic islets, liver, and adipocytes. The identification of more genes related to BMI expressed in the brain than in the adipocyte provides little information about the downstream pathways or organ systems involved. Indeed, pathway analysis identified genetic susceptibility to obesity as involving “insulin secretion/action, energy metabolism, lipid biology and adipogenesis” (1). Of the hundreds of single-nucleotide polymorphisms known to contribute to population risk of obesity, the affected gene, direction of effect, molecular mechanisms, tissues of action, and integrated physiological mechanism are only well-characterized for a handful. In one extensively studied example, obesity resulting from genetic disruption in leptin signaling is not necessarily mediated exclusively through hunger and energy

intake; the ob/ob mouse has markedly increased adiposity even when energy-restricted to prevent excessive weight gain (136).

### **Metabolic fuel concentrations in the blood are typically high, not low, in obesity (134)**

As with many physiological systems, causal mechanisms may be evident only during dynamic changes, not after compensation and re-establishment of a new homeostasis. For instance, sodium balance is negative initially, but not chronically, with thiazide diuretic treatment. Reduced circulating fuel concentrations have been documented early in the development of experimental obesity and several hours after a high-GL meal in humans, as considered above. As insulin resistance develops, metabolic fuel concentrations rise. Moreover, circulating fuels are at best a proxy for substrate sensing and oxidation; these may be dissociated under certain conditions, such as insulin resistance or diabetes. The CIM posits a state akin to “internal starvation”—an acceleration of fasting physiology emerging in the late postprandial period. Studies of cellular metabolism and energy sensing are needed to test this hypothesis.

### **Rodent studies of high-fat diets contradict the CIM (97)**

Low-carbohydrate diets have been reported to both cause (97) and prevent (98) adiposity in rodents, heterogeneity that may relate to confounding aspects of diets beyond GL and nondietary factors such as genetic background. Often, high-fat diets used in the laboratory contain not only high amounts of sugar, but also exceptionally high saturated fat content (94), which in rodents causes hyperinsulinemia, liver and muscle insulin resistance, and hypothalamic inflammation (137–143). The ensuing metabolic dysfunction shifts substrate partitioning toward adipose through mechanisms consistent with, not contrary to, the CIM (Figure 1). Substitution of unsaturated fat for saturated fat in these protocols, or ablation of toll-like receptor signaling, reduces metabolic dysfunction and adiposity (137–143).

### **Energy intake is not reduced by low- compared with high-carbohydrate diets in some feeding studies (135, 144)**

Low-carbohydrate diets have high energy density due to their high fat content. Changes in energy density influence food intake acutely (145), but this effect does not persist (17). Myriad factors of dubious relation to chronic energy balance—such as utensil size (146) or plate color (147)—influence acute consumption. The greater long-term weight loss when consuming high-fat diets than when consuming low-fat diets (16, 101–104) highlights the pitfalls of extrapolating chronic macronutrient effects from studies of a few weeks’ duration.

### **Energy expenditure is not increased by low- compared with high-carbohydrate diets in some feeding studies (128, 135)**

Short-term studies of metabolic outcomes may also produce misleading results, related to adaptive processes after changes in macronutrients. With initiation of a very-low-carbohydrate diet, ketones rise, providing an alternative fuel to the brain, thereby preserving lean mass. However, even with fasting, ketones do not reach a steady state until 3 wk (148); on a ketogenic diet,

nitrogen balance may remain negative (indicating lean mass breakdown) for 1 mo (149). An adaptive process of several weeks has also been observed with more moderate, nonketogenic macronutrient changes (150–152). In a recent meta-analysis, low- compared with high-carbohydrate diets slightly reduced energy expenditure in trials < 2.5 wk, but low-carbohydrate diets increased energy expenditure in longer trials (100). Contrary to theoretical concerns for experimental error (135), data from a large 5-mo study demonstrating increased energy expenditure when consuming a low-carbohydrate diet during weight-loss maintenance appear robust (106, 153, 154).

### **Weight loss is not substantially greater for low- than for high-carbohydrate diets in long-term trials (7, 125, 130, 131, 133, 135)**

Most diet trials have used low-intensity interventions to promote behavioral change. Most participants in these studies have difficulty sustaining dietary change, limiting inferences about efficacy. In the Pounds Lost (Preventing Obesity Using Novel Dietary Strategies) study (155), participants reported little difference in macronutrient intakes at 2 y and biomeasures of adherence (serum triglycerides, urinary nitrogen excretion) showed little differentiation between dietary groups. In DIET-FITS (Diet Intervention Examining The Factors Interacting with Treatment Success), weight loss was greater when consuming a low-carbohydrate than when consuming a low-fat diet at 3 and 6 mo, a difference that did not persist at 12 mo (156, 157). Of note, the low-fat diet included a focus on reducing refined carbohydrates, and both GI and GL decreased in this diet group. The DIRECT trial (Dietary Intervention Randomized Controlled Trial), in which participants received prepared meals to enhance adherence, reported greater weight loss with an ad libitum low-carbohydrate diet than with a calorie-restricted low-fat diet, which persisted at 2 y (158).

### **Some populations, such as in Asia, consume high-GL diets, yet they have relatively low rates of obesity**

The diets of subsistence farming societies were historically based on inexpensive, high-carbohydrate grains and tubers without the metabolic consequences suggested by the CIM. However, such ecological observations are subject to multiple interpretations, among them that people in these rural societies had high levels of occupational physical activity and restricted food availability, both of which might offset dietary influences on weight gain. Among Chinese with recent access to high-GL/high-sugar diets, obesity and metabolic disease have reached epidemic proportions (159). Beyond macronutrient changes, the “nutrition transition” in developing nations beginning in the 1970s (coincident with the low-fat diet era in the United States and Europe) is typified by replacement of traditional carbohydrates with processed starches and sugars that have a higher GL (160). In any event, many dietary and nondietary factors undoubtedly contribute to these trends.

### **Straw man argument**

Some critics assert that the CIM considers the actions of insulin only in the postprandial period and only in adipose tissue, noting

that insulin affects adiposity independently of carbohydrate (135). Clearly, insulin is a multifunctional hormone, secreted in response to numerous dietary and nondietary factors. However, the actions of carbohydrate on metabolism persist well beyond the postprandial state, as demonstrated by the “second meal effect,” wherein the GI of supper influences glucose tolerance the next day (161, 162), and by the effect of a low-carbohydrate diet on fasting insulin (163). Indeed, the CIM considers that substrate partitioning and fat deposition are determined by the integrated actions of insulin, together with other hormones and autonomic inputs, in multiple organs, not just adipose tissue (Figure 1). To avoid confusion, it should be recognized that the name of a scientific model typically reflects major distinguishing features—carbohydrate and insulin, here—not the full scope of causal factors and mechanistic relations.

Conversely, one might ask whether our formulation of the EBM is a straw man. In support of our argument, Supplemental Table 1 exemplifies the overwhelming dominance of energy balance in textbooks and professional society statements, and the importance of establishing a negative energy balance, chiefly through decreased intake. None of these articles, nor the recent dismissals of the CIM, provide a mechanistically oriented, testable model addressing dietary drivers of obesity, beyond the recurring focus on widely available, inexpensive, energy-dense, highly palatable, processed foods. The metabolic effects of diet, such as on substrate partitioning—a key distinguishing aspect of the CIM—do not feature in these iterations of the EBM. Illustrating this point, a scientific statement from the Endocrine Society on obesity pathogenesis concludes: “The impact of diet on obesity risk is explained largely by its effect on calorie intake, rather than by changes of either energy expenditure or the internal metabolic environment. Stated differently, ‘a calorie is a calorie.’ Thus, habitual consumption of highly palatable and energy-dense diets predisposes to excess weight gain irrespective of macronutrient content” (7).

### **Other logical fallacy**

Some might argue that new iterations of the CIM serve to “move the goalposts,” obscuring the contest of opposing ideas. However, the relevant question is whether developmental stages of a model offer a consistent distinction from conventional thinking. For the CIM, a clear distinction, implicit in iterations dating back a century (Table 1), entails reversal of the causal pathway linking diet, and specifically carbohydrates, to weight gain.

### **Resolving controversies**

The definitive research needed to resolve persisting controversies will be challenging. The average increase in body weight throughout the last half century is attributable to the storage of <1 g extra fat per day, illustrating the difficulty in exploring causal mechanisms with short-term studies. But this difficulty is no justification for basing scientific knowledge on inconclusive research (135). The failure of the low-fat diet for obesity, as advocated in the late 20<sup>th</sup> century, can be traced in part to reliance on weak evidence from short-term and confounded studies. Better funding for nutrition research and creative study designs will be needed, including for 1) mechanistically oriented feeding

**TABLE 1** Historical precedents regarding the carbohydrate-insulin model of obesity

| Year | Authors                      | Quotation  |
|------|------------------------------|--|
| 1924 | Harris (164)                 | “[O]ne of the causes of hyperinsulinism is the excessive ingestion of glucose-forming foods ... It is possible that the hunger incident to hyperinsulinism may be a cause of overeating, and, therefore, the obesity that so often precedes diabetes.”   |
| 1938 | Wilder and Wilbur (165)      | “[I]t seems that mobilization of fat from fat depots is resisted in obesity and that deposition is accelerated.... The effect after meals of withdrawing from the circulation even a little more fat than usual might well account both for the delayed sense of satiety and for the frequently abnormal taste for carbohydrate encountered in obese persons. Energy requirements must be satisfied one way or another, and if part of the food is made less available for metabolism, the result, as is the case in diabetes, inevitably is hunger. A slight tendency in this direction would have a profound effect in the course of time.”  |
| 1941 | Bauer (166)                  | “The current energy theory of obesity, which considers only an imbalance between intake of food and expenditure of energy, is unsatisfactory.... An increased appetite with a subsequent imbalance between intake and output of energy is the consequence of the abnormal anlage [predisposition] rather than the cause of obesity.”   |
| 1942 | Hetherington and Ranson (42) | “[High calorie intake and a sedentary life] may be only symptomatic, and not fundamental. It is not difficult to imagine, for example, a condition of hidden cellular semistarvation caused by a lack of easily utilizable energy-producing material, which would soon tend to force the body either to increase its general food intake, or to cut down its energy expenditure, or both.”   |
| 1953 | Pennington (167)             | “[Caloric restriction] reduces the weight of anyone, obese or lean, regardless of metabolic status, by opposing the homeostatic mechanism for maintaining energy balance. A more rational form of treatment, then, would be one which would enable the organism to establish a homeostatic equilibrium between caloric intake and expenditure at a normal level of body weight. In such a case, treatment would be directed primarily toward mobilization of the adipose deposits, and the appetite would be allowed to regulate the intake of food needed.... The use of a diet allowing an ad libitum intake of protein and fat and restricting only carbohydrate appears to meet the qualifications of such a treatment.” |
| 1957 | Thorpe (168)                 | “Restriction of carbohydrate intake removes the stimulus to insulin production, so that the fat storage activity of insulin will be held to a minimum. ... Fat will be mobilized from the adipose deposits of the body, oxidized to ketones in the liver, and circulated to the tissues in this easily combustible form.... [F]or it has long been known that, while carbohydrate can be readily converted into fat in the body, fat cannot be converted into carbohydrate in any significant amounts.”  |
| 1965 | Berson and Yalow (169)       | “The precise relationship of obesity to diabetes is not clear. We generally accept that obesity predisposes to diabetes; but does not mild diabetes predispose to obesity? Since insulin is a most potent lipogenic agent, chronic hyperinsulinism would favor the accumulation of body fat.”  |

studies of sufficient duration to distinguish transient from chronic macronutrient effects ( $\geq 1$  mo), focusing on determinants of individual predisposition to dietary effects; 2) clinical trials of efficacy with sufficient treatment intensity and fidelity to promote long-term behavior change ( $\geq 1$  y); and 3) cohort studies, ideally beginning in childhood, of the natural history of obesity ( $\geq 10$  y).

### Clinical and Public Health Translation

Calorie restriction for obesity treatment results in weight loss—initially—giving patients the impression they have conscious control over their body weight. But predictable biological responses oppose weight loss, including decreased metabolic rate and elevated hunger. Therefore, ongoing weight loss requires progressively more severe calorie restriction, even as hunger increases. Few people achieve clinically significant weight loss over the long term with this approach. Those who cannot might feel implicitly stigmatized as lacking in self-control.

Translation of the EBM to public health may be especially problematic. To prevent obesity, the USDA advises Americans to “stay within calorie limits” (4). Outside the research laboratory, there is no feasible way to measure individual energy requirements to a precision within 300 kcal/d. An overestimation of this magnitude would produce rapid weight gain. For practical

purposes, people must determine their dietary energy allowance empirically, as the amount with which body weight remains stable—yet another tautology.

According to the CIM, humans in the modern, industrial food environment may have greater long-term control over *what* than *how much* they eat. By reducing anabolic drive with a low-GL diet, patients may experience less hunger and improved energy level, promoting spontaneous weight loss in the same way that an antipyretic reduces fever without conscious control of heat balance. A practical strategy is to substitute high-GL foods (refined grains, potato products, concentrated sugars) with high-fat foods (e.g., nuts, seeds, avocado, olive oil), allowing for moderate intake of total carbohydrate from whole-kernel grains, whole fruits, and legumes and nonstarchy vegetables. For those with special susceptibility, such as high insulin secretion or severe insulin resistance, stricter reduction in total carbohydrate may be optimal.

### Conclusions

As with virtually all models of complex biological phenomena, the iteration of the CIM presented here cannot provide a complete and precise representation of all causal mechanisms; nor does it preclude the existence of other causative influences. The



value of a scientific model is in stimulating discourse and informing the design of research. Premature claims to have falsified or refuted the CIM, based on weak and confounded evidence, impede constructive scientific discourse. Controversy notwithstanding, important common ground may already exist. For instance, hardwired hedonic preferences for sweetness may drive consumption of sugary foods (consistent with the EBM), which in turn may also affect substrate partitioning through calorie-independent mechanisms (consistent with the CIM). In this sense, conventional notions of palatability and the metabolic effects of preferred foods would work in concert to drive fat accumulation. Or perhaps time-restricted eating could reduce hunger and thereby facilitate calorie restriction, in part through hormonal mechanisms (54).

The field of obesity should embrace paradigm clash as an essential step forward. Toward this end, investigators should, first, refrain from hyperbolic claims to have disproven (or proven) alternative explanations of the obesity pandemic; second, clarify the EBM, specifying contrasting causal and testable hypotheses; third, form collaborations among scientists with diverse viewpoints to test predictions in rigorous and unbiased research; and fourth, to facilitate these aims, depersonalize the debate, scrupulously avoiding ad hominem argument. Rigorous research using complementary designs will be needed to resolve the debate, clarify a middle ground, or point the way to new explanatory models that better encompass the evidence. With the massive and growing burden of obesity-related diseases throughout the world, this work must assume priority.

We thank Mitchell Lazar for critical feedback on the manuscript.

The authors' responsibilities were as follows—DSL: wrote the first draft of the manuscript and takes responsibility for design, writing, and the final content; LJA, AA, RdC, LCC, MIF, SBH, JDJ, JCK, RMK, DEL, GT, JSV, ECW, WCW, WSY, and CBE: participated in manuscript revision; and all authors: read and approved the final manuscript. DSL received grants to study the carbohydrate-insulin model from the NIH (USA) and philanthropies unaffiliated with the food industry, and royalties for books that recommend a carbohydrate-modified diet; his spouse owns a nutrition education and consulting business. LJA received consulting fees from and serves on advisory boards for ERX, Jamieson Wellness, Pfizer, Novo Nordisk, Sanofi, Janssen, UnitedHealth Group Ventures, and Gelesis; received research funding from Lilly, Janssen, Allurion, and Novo Nordisk; has an equity interest in Intellihealth, ERX, Zafgen, Gelesis, MYOS, and Jamieson Wellness; and serves on the board of directors for Intellihealth and Jamieson Wellness. AA is a member of the Scientific Advisory Boards for WW (USA), RNPC (France), Gelesis (USA), and Novo Nordisk A/S; and is currently employed by the Novo Nordisk Foundation to establish the National Centre for Healthy Weight in Denmark with the aim to prevent childhood obesity. LCC is founder of Faeth Therapeutics, a company that generates diets to enhance responses to cancer drugs. SBH is a member of the Scientific Advisory Board for Medifast. JDJ received research grants to study the role of hyperinsulinemia in metabolism from the Canadian Institutes of Health Research; and is cofounder and Board Chair of the Institute for Personalized Therapeutic Nutrition, a registered charity in Canada in which he has no financial interest. RMK is a member of the Scientific Advisory Boards of Virta Health, Day Two, and Seraphina Therapeutics; and received payments from JumpStartMD. GT received royalties for books that discuss the history, science, and therapeutic applications of carbohydrate-restricted eating. JSV received royalties for books on low-carbohydrate diets; is founder and has equity in Virta Health; and serves on the advisory board of Simply Good Foods. ECW received consulting fees from Hill United Health and founded Adapt Your Life, Inc. (equity interest)—both companies founded on low-carbohydrate-diet principles; and received royalties for books that

recommend a carbohydrate-restricted diet. WSY received grants to study low-carbohydrate (and other) eating patterns, consulted for Guideline Central on a clinical guideline about low-carbohydrate nutrition, and serves as a scientific advisor for dietdoctor.com. CBE received grants to study the carbohydrate-insulin model from the NIH (USA) and philanthropies unaffiliated with the food industry. All other authors report no conflicts of interest.

## Data availability

No original data were generated for this article.

## References

1. Locke AE, Kahali B, Berndt SI, Justice AE, Pers TH, Day FR, Powell C, Vedantam S, Buchkovich ML, Yang J, et al. Genetic studies of body mass index yield new insights for obesity biology. *Nature* 2015;518(7538):197–206.
2. Farooqi SI. Genetic, molecular and physiological mechanisms involved in human obesity: Society for Endocrinology Medal Lecture 2012. *Clin Endocrinol (Oxf)* 2015;82(1):23–8.
3. Yazdi FT, Clee SM, Meyre D. Obesity genetics in mouse and human: back and forth, and back again. *PeerJ* 2015;3:e856.
4. USDA and US Department of Health and Human Services (DHHS). *Dietary Guidelines for Americans, 2020–2025*. 9th ed. Washington (DC): USDA and US DHHS; 2020.
5. American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Expert Panel Report: guidelines (2013) for the management of overweight and obesity in adults. *Obesity (Silver Spring)* 2014;22(Suppl 2):S41–410.
6. Nonas CA, Dolins KR. Dietary intervention approaches to the treatment of obesity. In: Akabas SR, Lederman SA, Moore BJ, editors. *Textbook of obesity: biological, psychological and cultural influences*. 1st ed. Oxford, United Kingdom: Wiley-Blackwell; 2012. p. 295–309.
7. Schwartz RJ, Seeley RJ, Zeltser LM, Drewnowski A, Ravussin E, Redman LA, Leibel RL. Obesity pathogenesis: an Endocrine Society scientific statement. *Endocr Rev* 2017;38(4):267–96.
8. Blundell JE, Macdiarmid JI. Passive overconsumption. Fat intake and short-term energy balance. *Ann N Y Acad Sci* 1997;827:392–407.
9. Fazzino TL, Rohde K, Sullivan DK. Hyper-palatable foods: development of a quantitative definition and application to the US Food System Database. *Obesity (Silver Spring)* 2019;27(11):1761–8.
10. Tordoff MG, Pearson JA, Ellis HT, Poole RL. Does eating good-tasting food influence body weight? *Physiol Behav* 2017;170:27–31.
11. Johnson F, Wardle J. Variety, palatability, and obesity. *Adv Nutr* 2014;5(6):851–9.
12. Stubbs RJ, Whybrow S. Energy density, diet composition and palatability: influences on overall food energy intake in humans. *Physiol Behav* 2004;81(5):755–64.
13. Lalanza JF, Snoeren EMS. The cafeteria diet: a standardized protocol and its effects on behavior. *Neurosci Biobehav Rev* 2020;122: 92–119.
14. Naim M, Brand JG, Kare MR, Carpenter RG. Energy intake, weight gain and fat deposition in rats fed flavored, nutritionally controlled diets in a multichoice (“cafeteria”) design. *J Nutr* 1985;115(11): 1447–58.
15. Ramirez I. Overeating, overweight and obesity induced by an unpreferred diet. *Physiol Behav* 1988;43(4):501–6.
16. Tobias DK, Chen M, Manson JE, Ludwig DS, Willett W, Hu FB. Effect of low-fat diet interventions versus other diet interventions on long-term weight change in adults: a systematic review and meta-analysis. *Lancet Diabetes Endocrinol* 2015;3(12):968–79.
17. Saquib N, Natarajan L, Rock CL, Flatt SW, Madlensky L, Kealey S, Pierce JP. The impact of a long-term reduction in dietary energy density on body weight within a randomized diet trial. *Nutr Cancer* 2007;60(1):31–8.
18. Raynor HA, Steeves EA, Hecht J, Fava JL, Wing RR. Limiting variety in non-nutrient-dense, energy-dense foods during a lifestyle intervention: a randomized controlled trial. *Am J Clin Nutr* 2012;95(6):1305–14.
19. Poti JM, Braga B, Qin B. Ultra-processed food intake and obesity: what really matters for health-processing or nutrient content? *Curr Obes Rep* 2017;6(4):420–31.

20. Drewnowski A, Gupta S, Darmon N. An overlap between “ultraprocessed” foods and the preexisting Nutrient Rich Foods index? *Nutr Today* 2020;55(2):75–81.
21. Mayer-Gross W, Walker JW. Taste and selection of food in hypoglycaemia. *Br J Exp Pathol* 1946;27(5):297–305.
22. Page KA, Seo D, Belfort-DeAguiar R, Lacadie C, Dzuira J, Naik S, Amarnath S, Constable RT, Sherwin RS, Sinha R. Circulating glucose levels modulate neural control of desire for high-calorie foods in humans. *J Clin Invest* 2011;121(10):4161–9.
23. Strachan MW, Ewing FM, Frier BM, Harper A, Deary IJ. Food cravings during acute hypoglycaemia in adults with type 1 diabetes. *Physiol Behav* 2004;80(5):675–82.
24. Friedman MI. Food intake: control, regulation, and the illusion of dysregulation. In: Harris RBS, Mattes RD, editors. *Appetite and food intake: behavioral and physiological considerations*. Boca Raton, FL: CRC Press; 2008. p. 1–19.
25. Badman MK, Flier JS. The adipocyte as an active participant in energy balance and metabolism. *Gastroenterology* 2007;132(6):2103–15.
26. Apolzan JW, Bray GA, Smith SR, de Jonge L, Rood J, Han H, Redman LM, Martin CK. Effects of weight gain induced by controlled overfeeding on physical activity. *Am J Physiol Endocrinol Metab* 2014;307(11):E1030–7.
27. Norgan NG, Durmin JV. The effect of 6 weeks of overfeeding on the body weight, body composition, and energy metabolism of young men. *Am J Clin Nutr* 1980;33(5):978–88.
28. Roberts SB, Young VR, Fuss P, Fiatarone MA, Richard B, Rasmussen H, Wagner D, Joseph L, Holehouse E, Evans WJ. Energy expenditure and subsequent nutrient intakes in overfed young men. *Am J Physiol* 1990;259(3 Pt 2):R461–9.
29. Sims EA, Goldman RF, Gluck CM, Horton ES, Kelleher PC, Rowe DW. Experimental obesity in man. *Trans Assoc Am Physicians* 1968;81:153–70.
30. Leibel RL, Rosenbaum M, Hirsch J. Changes in energy expenditure resulting from altered body weight. *N Engl J Med* 1995;332(10):621–8.
31. Ludwig DS. The glycemic index: physiological mechanisms relating to obesity, diabetes, and cardiovascular disease. *JAMA* 2002;287(18):2414–23.
32. Bao J, Atkinson F, Petocz P, Willett WC, Brand-Miller JC. Prediction of postprandial glycemia and insulinemia in lean, young, healthy adults: glycemic load compared with carbohydrate content alone. *Am J Clin Nutr* 2011;93(5):984–96.
33. Wolever TM. Is glycaemic index (GI) a valid measure of carbohydrate quality? *Eur J Clin Nutr* 2013;67(5):522–31.
34. Atkinson FS, Brand-Miller JC, Foster-Powell K, Buyken AE, Goletzke J. International tables of glycemic index and glycemic load values 2021: a systematic review. *Am J Clin Nutr* 2021 July 13 (Epub ahead of print; doi: 10.1093/ajcn/nqab233).
35. Unger RH. Glucagon physiology and pathophysiology. *N Engl J Med* 1971;285(8):443–9.
36. Pfeiffer AFH, Keyhani-Nejad F. High glycemic index metabolic damage – a pivotal role of GIP and GLP-1. *Trends Endocrinol Metab* 2018;29(5):289–99.
37. Runchey SS, Valsta LM, Schwarz Y, Wang C, Song X, Lampe JW, Neuhauser ML. Effect of low- and high-glycemic load on circulating incretins in a randomized clinical trial. *Metabolism* 2013;62(2):188–95.
38. Pennant ME, Bluck LJ, Marcovecchio ML, Salgin B, Hovorka R, Dunger DB. Insulin administration and rate of glucose appearance in people with type 1 diabetes. *Diabetes Care* 2008;31(11):2183–7.
39. Ludwig DS, Majzoub JA, Al-Zahrani A, Dallal GE, Blanco I, Roberts SB. High glycemic index foods, overeating, and obesity. *Diabetics* 1999;103(3):E26.
40. Shimy KJ, Feldman HA, Klein GL, Bielak L, Ebbeling CB, Ludwig DS. Effects of dietary carbohydrate content on circulating metabolic fuel availability in the postprandial state. *J Endocr Soc* 2020;4(7):bvaa062.
41. Walsh CO, Ebbeling CB, Swain JF, Markowitz RL, Feldman HA, Ludwig DS. Effects of diet composition on postprandial energy availability during weight loss maintenance. *PLoS One* 2013;8(3):e58172.
42. Hetherington AW, Ranson SW. The spontaneous activity and food intake of rats with hypothalamic lesions. *Am J Physiol* 1942;136:609–17.
43. Pereira MA, Swain J, Goldfine AB, Rifai N, Ludwig DS. Effects of a low-glycemic load diet on resting energy expenditure and heart disease risk factors during weight loss. *JAMA* 2004;292(20):2482–90.
44. Goldsmith R, Joannisse DR, Gallagher D, Pavlovich K, Shamoon E, Leibel RL, Rosenbaum M. Effects of experimental weight perturbation on skeletal muscle work efficiency, fuel utilization, and biochemistry in human subjects. *Am J Physiol Regul Integr Comp Physiol* 2010;298(1):R79–88.
45. Scribner KB, Pawlak DB, Aubin CM, Majzoub JA, Ludwig DS. Long-term effects of dietary glycemic index on adiposity, energy metabolism, and physical activity in mice. *Am J Physiol Endocrinol Metab* 2008;295(5):E1126–31.
46. Gross LS, Li L, Ford ES, Liu S. Increased consumption of refined carbohydrates and the epidemic of type 2 diabetes in the United States: an ecologic assessment. *Am J Clin Nutr* 2004;79(5):774–9.
47. Ford ES, Dietz WH. Trends in energy intake among adults in the United States: findings from NHANES. *Am J Clin Nutr* 2013;97(4):848–53.
48. Friedman MI, Stricker EM. The physiological psychology of hunger: a physiological perspective. *Psychol Rev* 1976;83(6):409–31.
49. Bremer AA, Mietus-Snyder M, Lustig RH. Toward a unifying hypothesis of metabolic syndrome. *Pediatrics* 2012;129(3):557–70.
50. Johnson RJ, Sanchez-Lozada LG, Andrews P, Lanaspa MA. Perspective: a historical and scientific perspective of sugar and its relation with obesity and diabetes. *Adv Nutr* 2017;8(3):412–22.
51. Lyssiotis CA, Cantley LC. Metabolic syndrome: F stands for fructose and fat. *Nature* 2013;502(7470):181–2.
52. Taylor SR, Ramsamooj S, Liang RJ, Katti A, Pozovskiy R, Vasani N, Hwang S-K, Nahiyaan N, Francoeur NJ, Schattoff EM, et al. Dietary fructose improves intestinal cell survival and nutrient absorption. *Nature* 2021. <https://doi.org/10.1038/s41586-021-03827-2>.
53. Shukla AP, Dickison M, Coughlin N, Karan A, Mauer E, Truong W, Casper A, Emiliano AB, Kumar RB, Saunders KH, et al. The impact of food order on postprandial glycaemic excursions in prediabetes. *Diabetes Obes Metab* 2019;21(2):377–81.
54. de Cabo R, Mattson MP. Effects of intermittent fasting on health, aging, and disease. *N Engl J Med* 2019;381(26):2541–51.
55. Erion KA, Corkey BE. Hyperinsulinemia: a cause of obesity? *Curr Obes Rep* 2017;6(2):178–86.
56. Ludwig DS. The ketogenic diet: evidence for optimism but high-quality research needed. *J Nutr* 2020;150(6):1354–9.
57. Cusin I, Rohner-Jeanrenaud F, Terretaz J, Jeanrenaud B. Hyperinsulinemia and its impact on obesity and insulin resistance. *Int J Obes Relat Metab Disord* 1992;16(Suppl 4):S1–11.
58. Terretaz J, Cusin I, Etienne J, Jeanrenaud B. In vivo regulation of adipose tissue lipoprotein lipase in normal rats made hyperinsulinemic and in hyperinsulinemic genetically-obese (fa/fa) rats. *Int J Obes Relat Metab Disord* 1994;18(1):9–15.
59. Dallon BW, Parker BA, Hodson AE, Tippetts TS, Harrison ME, Appiah MMA, Witt JE, Gibbs JL, Gray HM, Sant TM, et al. Insulin selectively reduces mitochondrial uncoupling in brown adipose tissue in mice. *Biochem J* 2018;475(3):561–9.
60. Mehran AE, Templeman NM, Brigidi GS, Lim GE, Chu K-Y, Hu X, Botezelli JD, Asadi A, Hoffman BG, Kieffer TJ, et al. Hyperinsulinemia drives diet-induced obesity independently of brain insulin production. *Cell Metab* 2012;16(6):723–37.
61. Botezelli JD, Overby P, Lindo L, Wang S, Haida O, Lim GE, Templeman NM, Pauli JR, Johnson JD. Adipose depot-specific upregulation of Ucp1 or mitochondrial oxidative complex proteins are early consequences of genetic insulin reduction in mice. *Am J Physiol Endocrinol Metab* 2020;319(3):E529–E39.
62. Blüher M, Kahn BB, Kahn CR. Extended longevity in mice lacking the insulin receptor in adipose tissue. *Science* 2003;299(5606):572–4.
63. Bruning JC, Gautam D, Burks DJ, Gillette J, Schubert M, Orban PC, Klein R, Krone W, Müller-Wieland D, Kahn CR. Role of brain insulin receptor in control of body weight and reproduction. *Science* 2000;289(5487):2122–5.
64. Kim JK, Michael MD, Previs SF, Peroni OD, Mauvais-Jarvis F, Neschen S, Kahn BB, Kahn CR, Shulman GI. Redistribution of substrates to adipose tissue promotes obesity in mice with selective insulin resistance in muscle. *J Clin Invest* 2000;105(12):1791–7.
65. Torbay N, Bracco EF, Geliebter A, Stewart IM, Hashim SA. Insulin increases body fat despite control of food intake and physical activity. *Am J Physiol* 1985;248(1 Pt 2):R120–4.

66. Templeman NM, Skovso S, Page MM, Lim GE, Johnson JD. A causal role for hyperinsulinemia in obesity. *J Endocrinol* 2017;232(3): R173–83.
67. Page MM, Skovso S, Cen H, Chiu AP, Dionne DA, Hutchinson DF, Lim GE, Szabat M, Flibotte S, Sinha S, et al. Reducing insulin via conditional partial gene ablation in adults reverses diet-induced weight gain. *FASEB J* 2018;32(3):1196–206.
68. Cai X, Han X, Luo Y, Ji L. Comparisons of the efficacy of alpha glucosidase inhibitors on type 2 diabetes patients between Asian and Caucasian. *PLoS One* 2013;8(11):e79421.
69. Huang Z, Wang W, Huang L, Guo L, Chen C. Suppression of insulin secretion in the treatment of obesity: a systematic review and meta-analysis. *Obesity* 2020;28(11):2098–106.
70. Carlson MG, Campbell PJ. Intensive insulin therapy and weight gain in IDDM. *Diabetes* 1993;42(12):1700–7.
71. Astley CM, Todd JN, Salem RM, Vedantam S, Ebbeling CB, Huang PL, Ludwig DS, Hirschhorn JN, Florez JC. Genetic evidence that carbohydrate-stimulated insulin secretion leads to obesity. *Clin Chem* 2018;64(1):192–200.
72. Le Stunff C, Fallin D, Schork NJ, Bougnères P. The insulin gene VNTR is associated with fasting insulin levels and development of juvenile obesity. *Nat Genet* 2000;26(4):444–6.
73. Wermers RA, Fatourech V, Wynne AG, Kvoles LK, Lloyd RV. The glucagonoma syndrome. Clinical and pathologic features in 21 patients. *Medicine (Baltimore)* 1996;75(2):53–63.
74. Gasbjerg LS, Helsted MM, Hartmann B, Jensen MH, Gabe MBN, Sparre-Ulrich AH, Veedfald S, Stensen S, Lanng AR, Bergmann NC, et al. Separate and combined glucometabolic effects of endogenous glucose-dependent insulinotropic polypeptide and glucagon-like peptide 1 in healthy individuals. *Diabetes* 2019;68(5):906–17.
75. Irwin N, Gault VA, O'Harte FPM, Flatt PR. Blockade of gastric inhibitory polypeptide (GIP) action as a novel means of countering insulin resistance in the treatment of obesity-diabetes. *Peptides* 2020;125:170203.
76. Nauck MA, Meier JJ. Incretin hormones: their role in health and disease. *Diabetes Obes Metab* 2018;20(Suppl 1):5–21.
77. Fu Y, Kaneko K, Lin H-Y, Mo Q, Xu Y, Suganami T, Ravn P, Fukuda M. Gut hormone GIP induces inflammation and insulin resistance in the hypothalamus. *Endocrinology* 2020;161(9):bqaa102.
78. Boer GA, Keenan SN, Miotto PM, Holst JJ, Watt MJ. GIP receptor deletion in mice confers resistance to high-fat diet-induced obesity via alterations in energy expenditure and adipose tissue lipid metabolism. *Am J Physiol Endocrinol Metab* 2021;320(4):E835–E45.
79. Chandler-Laney PC, Morrison SA, Goree LL, Ellis AC, Casazza K, Desmond R, Gower BA. Return of hunger following a relatively high carbohydrate breakfast is associated with earlier recorded glucose peak and nadir. *Appetite* 2014;80:236–41.
80. Camps SG, Kaur B, Quek RYC, Henry CJ. Does the ingestion of a 24 hour low glycaemic index Asian mixed meal diet improve glycaemic response and promote fat oxidation? A controlled, randomized crossover study. *Nutr J* 2017;16(1):43.
81. Al-Dujaili EAS, Ashmore S, Tsang C. A short study exploring the effect of the glycaemic index of the diet on energy intake and salivary steroid hormones. *Nutrients* 2019;11(2):260.
82. Campfield LA, Smith FJ, Rosenbaum M, Hirsch J. Human eating: evidence for a physiological basis using a modified paradigm. *Neurosci Biobehav Rev* 1996;20(1):133–7.
83. Melanson KJ, Westerterp-Plantenga MS, Saris WH, Smith FJ, Campfield LA. Blood glucose patterns and appetite in time-blinded humans: carbohydrate versus fat. *Am J Physiol* 1999;277(2): R337–45.
84. Wyatt P, Berry SE, Finlayson G, O'Driscoll R, Hadjigeorgiou G, Drew DA, Khatib HA, Nguyen LH, Linenberg I, Chan AT, et al. Postprandial glycaemic dips predict appetite and energy intake in healthy individuals. *Nat Metab* 2021;3(4):523–9.
85. Lennerz B, Lennerz JK. Food addiction, high-glycemic-index carbohydrates, and obesity. *Clin Chem* 2018;64(1):64–71.
86. Sethi Dalai S, Sinha A, Gearhardt AN. Low carbohydrate ketogenic therapy as a metabolic treatment for binge eating and ultraprocesed food addiction. *Curr Opin Endocrinol Diabetes Obes* 2020;27(5): 275–82.
87. Friedman MI. Fuel partitioning and food intake. *Am J Clin Nutr* 1998;67(3):513S–18S.
88. Moulle VS, Picard A, Le Foll C, Levin BE, Magnan C. Lipid sensing in the brain and regulation of energy balance. *Diabetes Metab* 2014;40(1):29–33.
89. Scharrer E. Control of food intake by fatty acid oxidation and ketogenesis. *Nutrition* 1999;15(9):704–14.
90. Thompson DA, Campbell RG. Hunger in humans induced by 2-deoxy-D-glucose: glucoprivic control of taste preference and food intake. *Science* 1977;198(4321):1065–8.
91. Kanarek RB, Marks-Kaufman R, Ruthazer R, Gualtieri L. Increased carbohydrate consumption by rats as a function of 2-deoxy-D-glucose administration. *Pharmacol Biochem Behav* 1983;18(1):47–50.
92. Singer LK, York DA, Bray GA. Macronutrient selection following 2-deoxy-D-glucose and mercaptoacetate administration in rats. *Physiol Behav* 1998;65(1):115–21.
93. Kabir M, Rizkalla SW, Quignard-Boulangé A, Guerre-Millo M, Boillot J, Ardouin B, Luo J, Slama G. A high glycemic index starch diet affects lipid storage-related enzymes in normal and to a lesser extent in diabetic rats. *J Nutr* 1998;128(11):1878–83.
94. Ludwig DS, Ebbeling CB, Bikman BT, Johnson JD. Testing the carbohydrate-insulin model in mice: the importance of distinguishing primary hyperinsulinemia from insulin resistance and metabolic dysfunction. *Mol Metab* 2020;35:100960.
95. Pawlak DB, Bryson JM, Denyer GS, Brand-Miller JC. High glycemic index starch promotes hypersecretion of insulin and higher body fat in rats without affecting insulin sensitivity. *J Nutr* 2001;131(1):99–104.
96. Pawlak DB, Kushner JA, Ludwig DS. Effects of dietary glycemic index on adiposity, glucose homeostasis, and plasma lipids in animals. *Lancet* 2004;364(9436):778–85.
97. Hu S, Wang L, Togo J, Yang D, Xu Y, Wu Y, Douglas A, Speakman JR. The carbohydrate-insulin model does not explain the impact of varying dietary macronutrients on the body weight and adiposity of mice. *Mol Metab* 2020;32:27–43.
98. Kennedy AR, Pissios P, Otu H, Roberson R, Xue B, Asakura K, Furukawa N, Marino FE, Liu F-F, Kahn BB, et al. A high-fat, ketogenic diet induces a unique metabolic state in mice. *Am J Physiol Endocrinol Metab* 2007;292(6):E1724–39.
99. Ludwig DS. Dietary glycemic index and obesity. *J Nutr* 2000;130(2):280S–8S.
100. Ludwig DS, Dickinson SL, Henschel B, Ebbeling CB, Allison DB. Do lower-carbohydrate diets increase total energy expenditure? An updated and reanalyzed meta-analysis of 29 controlled-feeding studies. *J Nutr* 2021;151(3):482–90.
101. Bueno NB, de Melo IS, de Oliveira SL, da Rocha Ataíde T. Very-low-carbohydrate ketogenic diet v. low-fat diet for long-term weight loss: a meta-analysis of randomised controlled trials. *Br J Nutr* 2013;110(7):1178–87.
102. Mancini JG, Filion KB, Atallah R, Eisenberg MJ. Systematic review of the Mediterranean diet for long-term weight loss. *Am J Med* 2016;129(4):407–15.e4.
103. Mansoor N, Vinknes KJ, Veierød MB, Retterstøl K. Effects of low-carbohydrate diets v. low-fat diets on body weight and cardiovascular risk factors: a meta-analysis of randomised controlled trials. *Br J Nutr* 2016;115(3):466–79.
104. Sackner-Bernstein J, Kanter D, Kaul S. Dietary intervention for overweight and obese adults: comparison of low-carbohydrate and low-fat diets. A meta-analysis. *PLoS One* 2015;10(10):e0139817.
105. Chaput JP, Tremblay A, Rimm EB, Bouchard C, Ludwig DS. A novel interaction between dietary composition and insulin secretion: effects on weight gain in the Quebec Family Study. *Am J Clin Nutr* 2008;87(2):303–9.
106. Ebbeling CB, Feldman HA, Klein GL, Wong JMW, Bielak L, Steltz SK, Luoto PK, Wolfe RR, Wong WW, Ludwig DS. Effects of a low carbohydrate diet on energy expenditure during weight loss maintenance: randomized trial. *BMJ* 2018;363:k4583.
107. Ebbeling CB, Leidig MM, Feldman HA, Lovesky MM, Ludwig DS. Effects of a low-glycemic load vs low-fat diet in obese young adults: a randomized trial. *JAMA* 2007;297(19):2092–102.
108. Hron BM, Ebbeling CB, Feldman HA, Ludwig DS. Relationship of insulin dynamics to body composition and resting energy expenditure following weight loss. *Obesity* 2015;23(11):2216–22.
109. Pittas AG, Das SK, Hajduk CL, Golden J, Saltzman E, Stark PC, Greenberg AS, Roberts SB. A low-glycemic load diet facilitates greater weight loss in overweight adults with high insulin secretion but

- not in overweight adults with low insulin secretion in the CALERIE Trial. *Diabetes Care* 2005;28(12):2939–41.
110. Hjorth MF, Zohar Y, Hill JO, Astrup A. Personalized dietary management of overweight and obesity based on measures of insulin and glucose. *Annu Rev Nutr* 2018;38:245–72.
  111. Mattison JA, Colman RJ, Beasley TM, Allison DB, Kemnitz JW, Roth GS, Ingram DK, Weindruch R, de Cabo R, Anderson RM. Caloric restriction improves health and survival of rhesus monkeys. *Nat Commun* 2017;8(1):14063.
  112. Asai M, Ramachandrapa S, Joachim M, Shen Y, Zhang R, Nuthalapati N, Ramanathan V, Strohlic DE, Ferket P, Linhart K, et al. Loss of function of the melanocortin 2 receptor accessory protein 2 is associated with mammalian obesity. *Science* 2013;341(6143):275–8.
  113. Dubuc PU, Cahn PJ, Willis P. The effects of exercise and food restriction on obesity and diabetes in young ob/ob mice. *Int J Obes* 1984;8(3):271–8.
  114. Knebel B, Haas J, Hartwig S, Jacob S, Kollmer C, Nitzgen U, Muller-Wieland D, Kotzka J. Liver-specific expression of transcriptionally active SREBP-1c is associated with fatty liver and increased visceral fat mass. *PLoS One* 2012;7(2):e31812.
  115. Bray GA, York DA. Hypothalamic and genetic obesity in experimental animals: an autonomic and endocrine hypothesis. *Physiol Rev* 1979;59(3):719–809.
  116. Hustvedt BE, Lovo A, Reichl D. The effect of ventromedial hypothalamic lesions on metabolism and insulin secretion in rats on a controlled feeding regimen. *Ann Nutr Metab* 1976;20(4):264–71.
  117. Karakash C, Hustvedt BE, Lovo A, Le Marchand Y, Jeanrenaud B. Consequences of ventromedial hypothalamic lesions on metabolism of perfused rat liver. *Am J Physiol* 1977;232(3):E286–93.
  118. Lovo A, Hustvedt BE. Correlation between altered acetate utilization and hyperphagia in rats with ventromedial hypothalamic lesions. *Metabolism* 1973;22(12):1459–65.
  119. Penicaud L, Kinebanyan MF, Ferre P, Morin J, Kande J, Smadja C, Marfaing-Jallat P, Picon L. Development of VMH obesity: in vivo insulin secretion and tissue insulin sensitivity. *Am J Physiol* 1989;257(2 Pt 1):E255–60.
  120. McNay EC, Teske JA, Kotz CM, Dunn-Meynell A, Levin BE, McCrimmon RJ, Sherwin RS. Long-term, intermittent, insulin-induced hypoglycemia produces marked obesity without hyperphagia or insulin resistance: a model for weight gain with intensive insulin therapy. *Am J Physiol Endocrinol Metab* 2013;304(2):E131–8.
  121. Hjorth MF, Chaput JP, Ritz C, Dalskov SM, Andersen R, Astrup A, Tetens I, Michaelsen KF, Sjödin A. Fatness predicts decreased physical activity and increased sedentary time, but not vice versa: support from a longitudinal study in 8- to 11-year-old children. *Int J Obes* 2014;38(7):959–65.
  122. Richmond RC, Davey Smith G, Ness AR, den Hoed M, McMahon G, Timpson NJ. Assessing causality in the association between child adiposity and physical activity levels: a Mendelian randomization analysis. *PLoS Med* 2014;11(3):e1001618.
  123. Ludwig DS, Ebbeling CB. The carbohydrate-insulin model of obesity: beyond “calories in, calories out.” *JAMA Intern Med* 2018;178(8):1098–103.
  124. Bosy-Westphal A, Hagele F, Nas A. Impact of dietary glycemic challenge on fuel partitioning. *Eur J Clin Nutr* 2017;71(3):327–30.
  125. Bray GA, Heisel WE, Afshin A, Jensen MD, Dietz WH, Long M, Kushner RF, Daniels SR, Wadden TA, Tsai AG, et al. The science of obesity management: an Endocrine Society scientific statement. *Endocr Rev* 2018;39(2):79–132.
  126. Hall KD. A review of the carbohydrate-insulin model of obesity. *Eur J Clin Nutr* 2017;71(3):323–6.
  127. Hall KD. Did the food environment cause the obesity epidemic? *Obesity* 2018;26(1):11–13.
  128. Hall KD, Guo J. Obesity energetics: body weight regulation and the effects of diet composition. *Gastroenterology* 2017;152(7):1718–27.e3.
  129. Hall KD, Guo J, Speakman JR. Do low-carbohydrate diets increase energy expenditure? *Int J Obes* 2019;43(12):2350–4.
  130. Hall KD, Kahan S. Maintenance of lost weight and long-term management of obesity. *Med Clin North Am* 2018;102(1):183–97.
  131. Howell S, Kones R. “Calories in, calories out” and macronutrient intake: the hope, hype, and science of calories. *Am J Physiol Endocrinol Metab* 2017;313(5):E608–12.
  132. Schutz Y, Montani J-P, Dulloo AG. Low-carbohydrate ketogenic diets in body weight control: a recurrent plaguing issue of fad diets? *Obes Rev* 2021;22(Suppl 2):e13195.
  133. Sievenpiper JL. Low-carbohydrate diets and cardiometabolic health: the importance of carbohydrate quality over quantity. *Nutr Rev* 2020;78(Supplement\_1):69–77.
  134. Hall KD, Guyenet SJ, Leibel RL. The carbohydrate-insulin model of obesity is difficult to reconcile with current evidence. *JAMA Intern Med* 2018;178(8):1103–5.
  135. Speakman JR, Hall KD. Carbohydrates, insulin, and obesity. *Science* 2021;372(6542):577–8.
  136. Thurlby PL, Trayhurn P. The role of thermoregulatory thermogenesis in the development of obesity in genetically-obese (ob/ob) mice paired with lean siblings. *Br J Nutr* 1979;42(3):377–85.
  137. Milanski M, Degasperi G, Coope A, Morari J, Denis R, Cintra DE, Tsukumo DM, Anhe G, Amaral ME, Takahashi HK, et al. Saturated fatty acids produce an inflammatory response predominantly through the activation of TLR4 signaling in hypothalamus: implications for the pathogenesis of obesity. *J Neurosci* 2009;29(2):359–70.
  138. Benoit SC, Kemp CJ, Elias CF, Abplanalp W, Herman JP, Migrenne S, Lefevre A-L, Cruciani-Guglielmacci C, Magnan C, Yu F, et al. Palmitic acid mediates hypothalamic insulin resistance by altering PKC- $\theta$  subcellular localization in rodents. *J Clin Invest* 2009;119(9):2577–89.
  139. Cintra DE, Ropelle ER, Moraes JC, Pauli JR, Morari J, Souza CT, Grimaldi R, Stahl M, Carvalheira JB, Saad MJ, et al. Unsaturated fatty acids revert diet-induced hypothalamic inflammation in obesity. *PLoS One* 2012;7(1):e30571.
  140. Oliveira V, Marinho R, Vitorino D, Santos GA, Moraes JC, Dragano N, Sartori-Cintra A, Pereira L, Catharino RR, da Silva AS, et al. Diets containing  $\alpha$ -linolenic ( $\omega$ 3) or oleic ( $\omega$ 9) fatty acids rescues obese mice from insulin resistance. *Endocrinology* 2015;156(11):4033–46.
  141. Vijay-Kumar M, Vanegas SM, Patel N, Aitken JD, Ziegler TR, Ganji V. Fish oil rich diet in comparison to saturated fat rich diet offered protection against lipopolysaccharide-induced inflammation and insulin resistance in mice. *Nutr Metab (Lond)* 2011;8(1):16.
  142. Dornellas AP, Watanabe RL, Pimentel GD, Boldarine VT, Nascimento CM, Oyama LM, Ghebremeskel K, Wang Y, Bueno AA, Ribeiro EB. Deleterious effects of lard-enriched diet on tissues fatty acids composition and hypothalamic insulin actions. *Prostaglandins Leukot Essent Fatty Acids* 2015;102–103:21–9.
  143. Davis JE, Gabler NK, Walker-Daniels J, Spurlock ME. Tlr-4 deficiency selectively protects against obesity induced by diets high in saturated fat. *Obesity* 2008;16(6):1248–55.
  144. Hall KD, Guo J, Courville AB, Boring J, Brychta R, Chen KY, Darcey V, Forde CG, Gharib AM, Gallagher I, et al. Effect of a plant-based, low-fat diet versus an animal-based, ketogenic diet on ad libitum energy intake. *Nat Med* 2021;27(2):344–53.
  145. Bell EA, Rolls BJ. Energy density of foods affects energy intake across multiple levels of fat content in lean and obese women. *Am J Clin Nutr* 2001;73(6):1010–18.
  146. James LJ, Maher T, Biddle J, Broom DR. Eating with a smaller spoon decreases bite size, eating rate and *ad libitum* food intake in healthy young males. *Br J Nutr* 2018;120(7):830–7.
  147. Akyol A, Ayaz A, Inan-Eroglu E, Cetin C, Samur G. Impact of three different plate colours on short-term satiety and energy intake: a randomized controlled trial. *Nutr J* 2018;17(1):46.
  148. Owen OE, Caprio S, Reichard GA Jr, Mozzoli MA, Boden G, Owen RS. Ketosis of starvation: a revisit and new perspectives. *Clin Endocrinol Metab* 1983;12(2):359–79.
  149. Vazquez JA, Adibi SA. Protein sparing during treatment of obesity: ketogenic versus nonketogenic very low calorie diet. *Metabolism* 1992;41(4):406–14.
  150. Horton TJ, Drougas H, Brachey A, Reed GW, Peters JC, Hill JO. Fat and carbohydrate overfeeding in humans: different effects on energy storage. *Am J Clin Nutr* 1995;62(1):19–29.
  151. Clegg ME, Shafat A. A high-fat diet temporarily accelerates gastrointestinal transit and reduces satiety in men. *Int J Food Sci Nutr* 2011;62(8):857–64.
  152. Frahnow T, Osterhoff MA, Hornemann S, Kruse M, Surma MA, Klose C, Simons K, Pfeiffer AFH. Heritability and responses to high fat diet of plasma lipidomics in a twin study. *Sci Rep* 2017;7(1):3750.

153. Ludwig DS, Greco KF, Ma C, Ebbeling CB. Testing the carbohydrate-insulin model of obesity in a 5-month feeding study: the perils of post-hoc participant exclusions. *Eur J Clin Nutr* 2020;74(7):1109–12.
154. Ludwig DS, Lakin PR, Wong WW, Ebbeling CB. Scientific discourse in the era of open science: a response to Hall et al. regarding the Carbohydrate-Insulin Model. *Int J Obes* 2019;43(12):2355–60.
155. Sacks FM, Bray GA, Carey VJ, Smith SR, Ryan DH, Anton SD, McManus K, Champagne CM, Bishop LM, Laranjo N, et al. Comparison of weight-loss diets with different compositions of fat, protein, and carbohydrates. *N Engl J Med* 2009;360(9):859–73.
156. Gardner CD, Trepanowski JF, Del Gobbo LC, Hauser ME, Rigdon J, Ioannidis JPA, Desai M, King AC. Effect of low-fat vs low-carbohydrate diet on 12-month weight loss in overweight adults and the association with genotype pattern or insulin secretion: the DIETFITS randomized clinical trial. *JAMA* 2018;319(7):667–79.
157. Guo J, Robinson JL, Gardner CD, Hall KD. Objective versus self-reported energy intake changes during low-carbohydrate and low-fat diets. *Obesity* 2019;27(3):420–6.
158. Shai I, Schwarzfuchs D, Henkin Y, Shahar DR, Witkow S, Greenberg I, Golan R, Fraser D, Bolotin A, Vardi H, et al. Weight loss with a low-carbohydrate, Mediterranean, or low-fat diet. *N Engl J Med* 2008;359(3):229–41.
159. Wang Y, Zhao L, Gao L, Pan A, Xue H. Health policy and public health implications of obesity in China. *Lancet Diabetes Endocrinol* 2021;9(7):446–61.
160. Popkin BM, Adair LS, Ng SW. Global nutrition transition and the pandemic of obesity in developing countries. *Nutr Rev* 2012;70(1):3–21.
161. Axelsen M, Arvidsson Lenner R, Lonnroth P, Smith U. Breakfast glycaemic response in patients with type 2 diabetes: effects of bedtime dietary carbohydrates. *Eur J Clin Nutr* 1999;53(9):706–10.
162. Wolever TM, Jenkins DJ, Ocana AM, Rao VA, Collier GR. Second-meal effect: low-glycemic-index foods eaten at dinner improve subsequent breakfast glycemic response. *Am J Clin Nutr* 1988;48(4):1041–7.
163. Grey N, Kipnis DM. Effect of diet composition on the hyperinsulinemia of obesity. *N Engl J Med* 1971;285(15):827–31.
164. Harris S. Hyperinsulinism and dysinsulinism. *JAMA* 1924;83(10):729–33.
165. Wilder RM, Wilbur DL. Diseases of metabolism and nutrition. *Arch Intern Med* 1938;61:297–365.
166. Bauer J. Obesity: its pathogenesis, etiology and treatment. *Arch Intern Med* 1941;67(5):968–94.
167. Pennington AW. An alternate approach to the problem of obesity. *Am J Clin Nutr* 1953;1(2):100–6.
168. Thorpe GL. Treating overweight patients. *JAMA* 1957;165(11):1361–5.
169. Berson SA, Yalow RS. Some current controversies in diabetes research. *Diabetes* 1965;14(9):549–72.